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magnesium deficiency based on physiologic
principles as listed in the Table, but none 
provide data on the relative frequency of the
various causes in the general population or 
specific subgroups.6–9
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■ CLINICAL COMMENTARY
We need to know when magnesium
replacement improves patient outcomes
Treating the underlying cause of hypomagne-
semia makes sense. However, even though cli-
nicians often treat “the numbers,” it is not clear
that magnesium replacement therapy is benefi-
cial in the absence of symptoms caused by the
hypomagnesemia. For example, hypomagne-
semia is common for patients with acute
myocardial infarction, but magnesium replace-
ment therapy has not been shown to improve
outcomes in 2 large randomized trials, the
Fourth International Study of Infarct Survival
(ISIS 4)14 and Magnesium in Coronaries
(MAGIC).15 We need better-designed random-
ized trials to know for what clinical conditions
magnesium replacement leads to improved
patient-oriented outcomes. 
John Hickner, MD, MSc, Department of Family
Medicine, The University of Chicago Pritzker School 
of Medicine, Chicago, Ill
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What are effective therapies
for Clostridium difficile–
associated diarrhea?
■ EVIDENCE-BASED ANSWER
Oral metronidazole and oral vancomycin are
equally effective treatments for Clostridium dif-
ficile–associated diarrhea (CDAD) (strength of
recommendation [SOR]: A, based on random-
ized trials). Oral vancomycin is considerably
more expensive and may select for colonization
with vancomycin-resistant enterococci, leading
the American College of Gastroenterology to
recommend oral metronidazole as preferred
therapy (SOR: C, expert opinion). They recom-
mend therapy with vancomycin for those who
are pregnant, breast feeding, less than 10
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years old, nonresponders to metronidazole,
critically ill, or allergic or intolerant to metron-
idazole (SOR: C, expert opinion). 
Treat first recurrences the same as primary
infection. In persons with recurrent infection,
addition of the probiotic agent Saccharomyces
boulardii reduces the risk of further recur-
rences (SOR: B, single RCT). Little other evi-
dence exists to guide therapy for subsequent
recurrences.
■ EVIDENCE SUMMARY
Two randomized controlled trials have com-
pared the efficacy of oral metronidazole and oral
vancomycin for treatment of CDAD.1,2 Both stud-
ies demonstrated statistically equivalent cure
rates exceeding 90%, with relapse rates of 10%
to 20% for each drug. These small trials lacked
the power to detect small but potentially signif-
icant differences in treatment response. 
No published data exist indicating that van-
comycin is more effective than metronidazole 
in any clinical setting. A dose-range study
showed that 125 mg of oral vancomycin 4 times
a day is as effective as higher doses.3 Patients
who cannot take medication by mouth should
receive intravenous metronidazole, 500 mg 4
times per day. Unlike vancomycin, metronida-
zole achieves potentially effective concentra-
tions in the intestinal lumen following intra-
venous administration.4
Treatment of first recurrences of infection
with metronidazole or vancomycin produces
response rates similar to treatment of initial
Medical treatment of C difficile–associated diarrhea
Indication Treatment
First episode of C difficile–associated diarrhea Metronidazole, 500 mg orally 3 times daily 
(SOR: A; SOR: C for preference over vancomycin) for 10 days
First episode, allergy, or intolerance to metronidazole, Vancomycin, 125 mg orally 4 times daily 
pregnant, breast feeding, or age <10 years for 10 days
(SOR: A; SOR: C for preference over metronidazole)
Unable to take oral medication (SOR: C) Metronidazole 500 mg IV 4 times daily
First recurrence (SOR: C) As for first episode or Option #1 below
Second or greater recurrence:
Option #1 (SOR: B, single RCT) Metronidazole or vancomycin, plus S boulardii
(500 mg twice daily [3 x 1010 CFUs])
Option #2 (SOR: C) Vancomycin or metronidazole 
plus rifampin 300 mg 
oral twice daily for 10 days
Option #3 (SOR: C) Vancomycin tapered dose:
125 mg orally 4 times daily for 7 days
125 mg orally twice daily for 7 days
125 mg orally once daily for 7 days
125 mg orally every other day for 7 days
125 mg orally every 3 days for 14 days
Option #4 (SOR: C) Vancomycin plus cholestyramine 
4 g twice daily for 10 days
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infections.5 A minority of patients suffers multi-
ple relapses of infection, and there are few data
to guide therapy in this setting. 
A randomized, double-blinded, placebo-
controlled study evaluated the impact of adding
the probiotic agent Saccharomyces boulardii
to either metronidazole or vancomycin.6 For 
persons with recurrent infection, addition of 
S boulardii led to a 30% decrease in the absolute
risk of relapse (64% relapse vs 34%; number
needed to treat=3; P<.05). There was also a
nonsignificant trend toward reduced recurrences
in the treatment of primary infections. The 2
minor side effects noted with this treatment
were dry mouth (number needed to harm
[NNH]=11) and constipation (NNH=9). S
boulardii capsules are available from health food
stores and via the Internet. Several published
case series describe various additional approach-
es to therapy of recurrent CDAD (Table).
■ RECOMMENDATIONS FROM OTHERS
The American College of Gastroenterology and
the American College of Physicians treatment
guidelines for CDAD both call for treatment
with oral metronidazole 250 mg 4 times daily or
500 mg 3 times daily.7,8 The American College of
Gastroenterology recommends vancomycin (125
mg orally 4 times daily) when there is an intol-
erance or confirmed resistance to metronida-
zole, failure of response, when the patient is
pregnant, breast feeding, or under 10 years of
age, critically ill from colitis, or when the diar-
rhea could be related to Staphylococcus aureus.
In milder cases, treatment may involve only dis-
continuation of antibiotics and supportive thera-
py with observation. Opiates and antispasmod-
ics should be avoided. These guidelines do not
recommend any treatment over another for ther-
apy of multiple recurrences. 
Michael E. Ohl, MD, James J. Stevermer, MD,
MSPH, Susan Meadows, MLS, Department of Family
and Community Medicine, University of Missouri–Columbia
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■ CLINICAL COMMENTARY
Discontinue the offending antibiotic and
treat the infection; prevent outbreaks via
patient-to-patient transmission
Most cases of Clostridium difficile–associated
diarrhea are caused by antibiotic use; it is
therefore one of the most common nosocomial
infections. In addition to discontinuing use of
the offending antibiotic and treating the infec-
tion, it is also important to prevent further out-
breaks via patient-to-patient transmission. In
our hospital, once a patient is diagnosed with
C difficile, contact precautions are instituted. If
the patient is incontinent, isolation in a single
room is required. If the patient is continent
For those with recurrent infection,
addition of S boulardii decreased
the absolute risk of relapse by 30%
